Podcast Episodes
Back to Search
Ep. 379 - Argenx M&A, AI giants and biopharma, catalyst scorecard
Season 7 Episode 379
Argenx the tier-jumping European biotech, believes its proposed $2.2 billion purchase of Forte Biosciences will add a second multi-indication product…
3 months, 3 weeks ago
Ep. 378 - U.K. cabinet shuffle, Taiwan biotech and Biogen data
The departure of U.K. Science Minister Patrick Vallance is a blow for U.K. biotech. On the latest BioCentury This Week podcast, BioCentury’s analysts…
4 months ago
Ep. 377 - Trends in life sciences talent with CBRE's Ian Anderson
Season 7 Episode 377
After nearly three years of sluggish job growth, hiring is turning a corner in the U.S. life sciences industry, while the talent pool is expanding be…
4 months ago
Ep. 376 - M&A momentum: 3Q public markets preview
Season 7 Episode 376
M&A enthusiasm is carrying biotech amid tepid reception for launches. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss BioCe…
4 months, 1 week ago
Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotech
Season 7 Episode 375
Novartis is deepening its antibody-drug conjugate capabilities with its $1.1 billion acquisition of U.K. biotech Myricx Pharma. On the latest episode…
4 months, 2 weeks ago
Ep. 374 - Parkinson's deep dive & FDA trial reforms
Season 7 Episode 374
New Parkinson’s disease programs aim to move beyond the historical norm of symptom management, branching into targeted therapeutics and cell therapie…
4 months, 3 weeks ago
Ep. 373 - AbbVie M&A, FDA reversals, a CAR T first
Season 7 Episode 373
AbbVie's $10.9 billion deal to acquire Apogee will expand its immunology pipeline by delivering assets for atopic dermatitis and asthma. On the lates…
4 months, 4 weeks ago
Ep. 372 - Biotech IPOs, Biosecure Act, cachexia pipeline
Season 7 Episode 372
Biotech IPOs that are getting out remain hot — but will that continue into the fall? On the latest BioCentury This Week podcast, BioCentury’s analyst…
5 months ago
Ep. 371 - Moving faster at the academia-industry interface
Season 7 Episode 371
Getting into the clinic fast to de-risk assets has become the name of the game in biotech, and at the academia-industry interface, too.
From AI to NAM…
5 months, 1 week ago
Ep. 370 - Calmer waters for FDA; Servier, Lilly deals
Season 7 Episode 370
FDA’s new leadership is sailing the agency into calmer waters amid a search for a permanent commissioner and permanent center directors. On the lates…
5 months, 1 week ago